(Q33587369)

English

CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

based on heuristic

inferred from title

Shingo Matsumoto

9

object named as

Shingo Matsumoto

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

11

object named as

Kiyotaka Yoh

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

15

object named as

Koichi Goto

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

16

object named as

Atsushi Ochiai

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Genichiro Ishii

17

object named as

Genichiro Ishii

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Masahiro Tsuboi

13

object named as

Masahiro Tsuboi

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

2

object named as

Shinya Neri

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Masayuki Ishibashi

1

object named as

Masayuki Ishibashi

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Hiroko Hashimoto

3

object named as

Hiroko Hashimoto

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

7

object named as

Hibiki Udagawa

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

8

object named as

Keisuke Kirita

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Shigeki Umemura

10

object named as

Shigeki Umemura

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

12

object named as

Seiji Niho

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Kenkichi Masutomi

14

object named as

Kenkichi Masutomi

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

Tomoyuki Miyashita

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Tatsuya Yoshida

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Yuka Nakamura

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

language of work or name

0 references

publication date

21 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Scientific Reports

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

46662

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

copyright license

Creative Commons Attribution 4.0 International

21 April 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Cancer cell invasion driven by extracellular matrix remodeling is dependent on the properties of cancer-associated fibroblasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Investigation of the freely available easy-to-use software 'EZR' for medical statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Fibroblasts associated with cancer cells keep enhanced migration activity after separation from cancer cells: a novel character of tumor educated fibroblasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Visualizing spatiotemporal dynamics of multicellular cell-cycle progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa")

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Down-regulation of the macrophage lineage through interaction with OX2 (CD200)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5399371

21 June 2018

Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.

1 reference

https://api.crossref.org/works/10.1038%2FSREP46662

21 January 2018

Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28429795

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Grading System of Lung Adenocarcinomas Based on Histologic Pattern is Predictive of Disease Recurrence in Stage I Tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/28429795

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28429795

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SREP46662

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33587369&oldid=2195527490"